CovClear Ultra Sensitive Rapid Antigen Test ($18.00/unit)
CovClear Ultra Sensitive Rapid Antigen Test ($18.00/unit)
CovClear Ultra Sensitive Rapid Antigen Test ($18.00/unit)
  • Load image into Gallery viewer, CovClear Ultra Sensitive Rapid Antigen Test ($18.00/unit)
  • Load image into Gallery viewer, CovClear Ultra Sensitive Rapid Antigen Test ($18.00/unit)
  • Load image into Gallery viewer, CovClear Ultra Sensitive Rapid Antigen Test ($18.00/unit)

CovClear Ultra Sensitive Rapid Antigen Test ($18.00/unit)

Regular price
$900.00
Sale price
$900.00
Regular price
$1,000.00
Sold out
Unit price
per 

The CovClear Rapid Antigen test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasal swab specimens. 

  • 98.5% Sensitivity
  • 100% Specificity 
  • Simple to use – Rapid Results in 3-20 Minutes

  • Highly Sensitive and Specific – Outperforming other antigen tests

  • Safety Advantage – Sealed Vial Protecting Collector Against Live Virus

  • No Reader Required – Reduced Cost

  • No Cassette Needed – Reduced Material Wastage

  • Early Detection – Reduced Exposure

  • Can be purchased for use under a CLIA license or for a surveillance program
  • Researched, developed & manufactured in the USA

 CovClear has received CE marking for sale in the European Union.

 

50 tests per box. 

****Orders on 500+ tests will be discounted****

 

Intended Use:

The CovClear™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasal swab specimens directly collected. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high complexity tests, and at the Point of Care (POC), i.e., in patient care settings operating under a high complexity CLIA Certificate. Results are for the identification of the SARS-CoV-2 nucleocapsid protein antigen. The antigen is generally detectable in nasal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out a bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. Negative results are presumptive and confirmation with a molecular assay, if necessary, for patient management may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19. The CovClear™ COVID-19 Antigen Test is intended for use by medical professionals or trained operators who are proficient in performing tests and trained clinical laboratory personnel or individuals trained in Point of Care settings. The CovClear™ COVID-19 Antigen Test is only for use under the Food and Drug Administration’s Emergency Use Authorization (EUA).